US pharmaceutical company Eli Lilly saw sales of its weight loss and anti-diabetes GLP-1 drugs soar in 2025, and it is preparing to sell a pill version of the drug in 2026 (CNBC, Fierce Pharma). The question will be suspended on 31 December 2026 and the outcome determined using revenue data as reported by Eli Lilly in its fourth quarter report, expected in February 2027 (Eli Lilly - Quarterly Results, see "FINANCIAL WORKBOOK" files and see the "[Year] Revenue" sheet). For the purposes of this question, "GLP-1 drugs" include GLP-1 agonists and dual GLP-1/GIP receptor agonists (Cleveland Clinic). Sales of drugs that combine a GLP-1 drug with other compounds will count. As of the launch of this question, Eli Lilly was marketing three GLP-1 drugs: Mounjaro, Trulicity, and Zepbound. Sales of the same drug or drugs being sold under a different name will count. If Eli Lilly begins to sell other GLP-1 drugs (e.g., orforglipron and retatrutide) and reports revenue for those drugs, those revenues will be included in the total for resolution (PharmExec). In 2025, Eli Lilly's total revenue from GLP-1 drugs was $40.783 billion, up from $21.719 billion in 2024.

Confused? Check our FAQ or ask us for help. To learn more about Good Judgment and Superforecasting, click here.

To learn more about how you can become a Superforecaster, see here. For other posts from our Insights blog, click here.